| Company Name: |
Shanghai Hongye Biotechnology Co. Ltd
|
| Tel: |
400-9205774 |
| Email: |
sales@glpbio.cn |
| Products Intro: |
Product Name:LAS191859
CAS:1420071-13-1
Purity:>98% Package:1mg;10mg;50mg;100mg;
|
| Company Name: |
ChemeGen(Shanghai) Biotechnology Co.,Ltd.
|
| Tel: |
18818260767 |
| Email: |
sales@chemegen.com |
| Products Intro: |
Product Name:LAS191859
CAS:1420071-13-1
Purity:98% Package:10 mg;50 mg;100 mg;500 mg;1 g;5 g;10 g
|
| Company Name: |
TargetMol Chemicals Inc.
|
| Tel: |
4008200310 |
| Email: |
marketing@tsbiochem.com |
| Products Intro: |
Product Name:LAS191859;LAS191859
CAS:1420071-13-1
Purity:98% Package:5 mg
|
| Company Name: |
Nanjing Tengyi Biotechnology Co., Ltd
|
| Tel: |
025-58851786 17714337195 |
| Email: |
sales@tybiochem.com |
| Products Intro: |
Product Name:1-[2-[[(cyclopropylcarbonyl)ethylamino]methyl]-4-(trifluoromethyl)phenyl]-6-methyl-1H-pyrrolo[2,3-b]pyridine-3-aceticacid
CAS:1420071-13-1
Purity:95+% Package:1g;5g
|
|
| | LAS191859 Basic information |
| Product Name: | LAS191859 | | Synonyms: | LAS191859;1H-Pyrrolo[2,3-b]pyridine-3-acetic acid, 1-[2-[[(cyclopropylcarbonyl)ethylamino]methyl]-4-(trifluoromethyl)phenyl]-6-methyl-;1-[2-[[(cyclopropylcarbonyl)ethylamino]methyl]-4-(trifluoromethyl)phenyl]-6-methyl-1H-pyrrolo[2,3-b]pyridine-3-aceticacid | | CAS: | 1420071-13-1 | | MF: | C24H24F3N3O3 | | MW: | 459.46 | | EINECS: | | | Product Categories: | | | Mol File: | 1420071-13-1.mol |  |
| | LAS191859 Chemical Properties |
| storage temp. | Store at -20°C | | solubility | DMF: 20 mg/ml; DMSO: 20 mg/ml; DMSO:PBS (pH 7.2) (1:2): 0.33 mg/ml; Ethanol: 2.5 mg/ml | | form | A crystalline solid |
| | LAS191859 Usage And Synthesis |
| Description | LAS191859 is a CRTH2/DP2 antagonist with IC50 values of 9.58, 14, 15.5, and 7.6 nM for recombinant human, rat, mouse, and guinea pig CRTH2/DP2 receptors, respectively. In vitro evidence in GTPγS binding studies indicate that LAS191859 is a CRTh2 antagonist with activity in the low nanomolar range. This potency is also maintained in cellular assays performed with human eosinophils and whole blood. The main differentiation of LAS191859 vs other CRTh2 antagonists is in its receptor binding kinetics. LAS191859 has a residence time half-life of 21h at CRTh2 that translates into a long-lasting in vivo efficacy that is independent of plasma levels |
| | LAS191859 Preparation Products And Raw materials |
|